Breast metastasis from primary lung adenocarcinoma in a young woman: A case report and literature review

Diego Enrico, Silvia Saucedo, Inés Bravo

BACKGROUND
Breast metastasis from extra mammary malignancies is rare. An incidence of 0.2%-1.3% has been reported in the literature, including that from different types of malignant neoplasms.

CASE SUMMARY
We present a case of a 29-year-old nonsmoking woman with breast metastasis from lung adenocarcinoma. Computed tomography revealed atelectasis in the right middle lobe of the lung and ipsilateral pleural effusion. Additionally, on physical examination, a small mass was noted in her right breast. The patient underwent bronchoscopy, needle thoracentesis, and breast biopsy. Following cytology, histology and immunohistochemical analyses, primary lung adenocarcinoma with metastasis to the breast was diagnosed. Only 63 cases, including our patient, have been reported in the literature since 2000, and this is the second in a woman under 30 years of age.

CONCLUSION
This atypical presentation may cause a significant diagnostic dilemma, but the contribution of immunohistochemistry is crucial to the accuracy of the final diagnosis.

Key words: Lung cancer; Breast metastasis; Immunohistochemistry; Lymphatic spreading; Case report

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: We present the second case of lung adenocarcinoma with metastasis to the breast in a patient under 30 years of age. This is a rare entity in oncology and even more
INTRODUCTION

Primary breast cancer is the most common malignancy in adult females. However, metastatic involvement of the breast is a rare phenomenon, with a reported frequency of approximately 0.2%-1.3%[1]. A variety of neoplasms have been reported to metastasize to the breast, including malignant melanoma, lymphoma, lung, ovary, prostate, kidney, stomach, ileum, thyroid, and cervical cancer[2]. Despite its rarity, metastatic breast disease from lung adenocarcinoma poses a significant diagnostic dilemma.

Lung cancer is the leading cause of cancer death, with one of the highest incidences. However, to date, there have been a few published cases of lung adenocarcinoma metastasizing to the breast. We report the case of a patient with breast metastasis from primary lung adenocarcinoma. To the best of our knowledge, this is the second report of this entity in a woman under 30 years of age.

CASE PRESENTATION

Chief complaints and history of illness

A 29-year-old nonsmoking nurse presented with a 3-wk history of dry cough to the Eva Perón General Hospital, San Martín (Buenos Aires), Argentina.

Imaging examinations and physical examination

Routine chest X-ray followed by computed tomography (CT) revealed atelectasis in the right middle lobe of the lung, ipsilateral pleural effusion, and enlarged lymph nodes in the mediastinum and right hilum (Figure 1). On physical examination, a small mass was noted in the upper outer field quadrant of her right breast. Axillary and cervical chain lymph nodes were not palpable. Mammography did not reveal any suspicious images. However, ultrasonography (US) satisfactorily showed a hypoechoic solid nodule (11.6 mm x 6.6 mm x 8.9 mm) in the right breast, which was biopsied with a trucut needle (Figure 2).

The patient underwent bronchoscopy, which revealed submucosal infiltration causing a about 50% obstruction of the right middle lobe bronchus. During the bronchial procedure, washing, brushing and biopsies were obtained. Furthermore, needle thoracentesis was performed.

Based on all this information, the main differential diagnoses considered were a primary breast tumor with lung and pleural metastasis or two synchronous primary tumors.

Cytological findings

All the cytological specimens (pleural effusion, bronchial washing, and bronchial brushing) were stained using the Papanicolaou technique, and the diagnosis of adenocarcinoma was suggested.

Histopathological and immunohistochemical findings

Hematoxylin-eosin (HE) staining and immunohistochemistry (IHC) were performed on formalin-fixed paraffin embedded tissues from bronchoscopy biopsy and core-needle breast biopsy. On both biopsies (bronchial mucosa and breast), HE-stained paraffin sections revealed infiltration by adenocarcinoma (Figure 3). Additionally, no evidence of in situ carcinoma was observed on the breast specimen. IHC (performed...
Figure 1 Chest computed tomography scan. Atelectasis in the right middle lobe of the lung, ipsilateral pleural effusion, and enlarged lymph nodes in the mediastinum and right hilum.

on a BenchMark XT autostainer, Ventana Medical Systems Inc, Tucson, AZ) of lung and breast specimens revealed strong immunoreactivity for anti-pancytokeratin AE1AE3, cytokeratin 7 (CK7), thyroid transcription factor-1 (TTF-1), and napsin A. The neoplastic cells lacked expression of cytokeratin 20 (CK20), P63, estrogen receptor (ER), progesterone receptor (PR), HER2/neu, and GATA3 (Figure 3).

Molecular findings
Epidermal growth factor receptor mutations in exons 19 to 21 were negative (PCR-based pyrosequencing assay), as was EML4-ALK rearrangement by fluorescence in situ hybridization (FISH).

FINAL DIAGNOSIS
The histology and immunohistochemical staining pattern were strongly consistent with metastasis to the breast from primary lung adenocarcinoma.

TREATMENT
In February 2016, the patient was started on treatment with cisplatin and pemetrexed. After an initial response, she experienced lung progression, and docetaxel was used as a second-line therapy to achieve stable disease.

OUTCOME AND FOLLOW-UP
Due to the deterioration of her clinical conditions, a third-line therapy was not feasible, and she continued with palliative supportive care. Her overall survival was 20 mo.

DISCUSSION
Literature review
Since 2000, 63 cases of breast metastasis from a lung adenocarcinoma have been reported in the literature, including our patient (Table 1)[1-44]. The median age was 56 years (SD 13.4), and as expected, the majority were female (82.5%), while only 8 (12.7%) patients with breast metastasis were men.

Of the 43 patients with data about the side of disease, 35 (81.4%) had evidence of disease in both lung and breast on the same side, while 6 (14%) had contralateral and 3 (7%) had bilateral breast involvement. A statistical correlation was observed between the side of the primary lung cancer and the side of the breast metastasis ($P < 0.001$).

The distribution of immunohistochemical markers in the literature is shown in Figure 4. The most frequent markers analyzed were TTF-1, CK7, CK20, napsin A, ER, PR, HER2, GCDFP-15, mammaglobin, and GATA3. There were six cases with negative TTF-1, three with negative napsin A, and only one with negative CK7.
Figure 2  Right breast ultrasound. Hypoechoic solid nodule (11.6 mm x 6.6 mm x 8.9 mm).

Discussion
The most common sites of lung cancer metastasis are the bones, lungs, brain, adrenal glands, liver, and extrathoracic lymph nodes, in descending order[45]. However, autopsy series have revealed that lung cancer may metastasize to nearly any organ. Williams et al[46] published the most extensive series, which included 169 cases of metastases to the breast from extra mammary solid tumors and reported that the most common histological type was malignant melanoma.

Distinguishing a breast metastasis from a primary breast cancer, based on mammography, may be extremely difficult since metastasis can mimic a primary malignancy or even a benign lesion. The absence of micro calcifications is considered a characteristic of metastatic lesions to the breast, with the exception of ovarian cancer[47]. On mammography, usually single lesions are observed, but sometimes multiple well-circumscribed lesions may be present[13]. In our case, there were no mammographic findings, and the breast lesion was discovered by ultrasonography. Although most of the lesions do not show any specific histological features, some authors have described different characteristics of breast metastasis from extra mammary malignancies. These features include a circumscribed tumor with multiple satellite foci, the presence of many lymphatic emboli and the absence of an intraductal component, which is the most relevant characteristic[1].

As outlined above, the distinction between metastasis from lung adenocarcinoma and primary breast adenocarcinoma may cause a diagnostic dilemma. For this, the contribution of immunohistochemistry is crucial. There is no single marker with 100% sensitivity and specificity that can solve this problem, hence an immunohistochemical panel is needed. Both breast and lung adenocarcinomas have overlapping CK7+/CK20- immunoprofiles in most cases. The frequency of ER expression in lung adenocarcinoma has been reported to vary from 7.6% to 27.2%, depending on the antibody used[48]. TTF-1 is positive in 73%–88% of lung adenocarcinoma cases, and there are very few reports of its positivity in breast cancer (less than 3% at least weakly or focally)[49]. Napsin A staining has been reported to be positive in 80%-90% of lung adenocarcinoma cases. This marker is usually negative in breast cancer, even though it has been found to be positive in less than 3% of breast adenocarcinoma cases[50]. Although TTF-1 is a reliable marker for lung adenocarcinoma, napsin A is more sensitive and specific. The combination of both markers provides the maximum benefit. On the other hand, 67%-95% of breast cancer cases express GATA3 (43%-73% of triple-negative cases), and its expression in lung adenocarcinomas is less than 10%[51].

Our patient had metastasis to her right breast, which is the same side affected by the malignant pleural effusion, consistent with the hypothesis by Huang et al[25]. To this end, they considered a stepwise mechanism involving parietal pleural seeding, followed by invasion into chest wall lymphatic vessels draining to ipsilateral axillary lymph nodes and retrograde lymphatic spreading to the breast. This mechanism of breast metastasis could be supported by findings of enlarged homolateral axillary lymph nodes. Moreover, Barber et al[52] demonstrated lymphatic communication between the breast and mediastinal lymphatic channels. These hypotheses could be confirmed by the fact that almost 80% of the cases reported from 2000 to date had ipsilateral lesions. Another potential type of spread could be hematogenous. However, if lung cancer spreads through this route, both breasts should have the same probability of being affected. This is not reflected in the reviewed cases, where only 5.4% of patients had bilateral breast involvement. The last possible explanation could be direct tumor invasion through the chest wall to the breast, but chest CT scans
Breast biopsy showed adenocarcinoma infiltrating into the adjacent parenchyma. A: Ducts were not involved by the tumor, and no evidence of in situ carcinoma was obtained (x 40); B: Bronchoscopy biopsy (HE) showed poorly differentiated adenocarcinoma (x 40); C, D: Immunohistochemical staining for thyroid transcription factor-1 was positive on both breast (C) and lung specimens (D); E, F: GATA3 staining was negative in both breast (E) and lung tissue (F).

did not reveal this alteration in the reported cases. Therefore, lymphatic spreading might be the most reasonable mechanism of lung cancer dissemination to the breast.

**CONCLUSION**

Here, we present a rare case of synchronous isolated metastasis to the breast from lung adenocarcinoma in a young patient. This is the second report, together with that by Wang et al.[14], in a woman under 30 years of age. Due to the infrequency of this phenomenon, the diagnosis may cause a significant dilemma. Clinical examination, radiological assessment, and pathological evaluation are essential. Nonetheless, in our opinion, immunohistochemistry makes a difference, playing a key role in the accuracy of the final diagnosis.
| Ref. | Sex/age | Lung cancer | Breast metastasis | IHC markers of breast biopsy |
|------|---------|-------------|------------------|-----------------------------|
| Lee et al[3], 2000 (2 cases) | NA/NA | NA | NA | NA |
| Masmoudi et al[4], 2003 | Female/54 | NA | NA | NA |
| Ramar et al[3], 2003 | Male/56 | Right | Right | CK7-; CK20-; CAM 5.2-; ER-; PR-; CDP- |
| Yeh et al[5], 2004 | Female/44 | NA | Right | NA |
| Komorowski et al[4], 2005 | NA/48 | NA | NA | NA |
| Gómez-Caro et al[4], 2006 | Male/65 | Left | Left | CK4+; CK7+; TTF-1- |
| Lee[3], 2007 | Female/64 | NA | NA | NA |
| Ucar et al[8], 2007 | Male/63 | Left | Left | CK7+; TTF-1- |
| Ho et al[9], 2007 | Male/71 | Right | Left | NA |
| Komorowski et al[7], 2005 | NA/48 | NA | NA | NA |
| Gómez-Caro et al[8], 2006 | Male/65 | Left | Left | CK4+; CK7+; TTF-1- |
| Yeh et al[6], 2004 | Female/44 | NA | Right | NA |
| Klingen et al[10], 2007 | Male/71 | Right | Left | NA |
| Yoon et al[11], 2010 | Female/42 | Left | Left | TTF-1+; E-cadherin+; ER-; PR-; CK5/6-; Thyroglobulin- |
| Nasit et al[12], 2011 | Female/42 | Right | Bilateral | TTF-1+ |
| Fukumoto et al[13], 2011 | Female/65 | Left | Left | TTF-1+; CK7+; CEA+; GCDFP15+; Mammaglobin+; CK 5/6 +; Calretinin +; CA125+; |
| Li et al[14], 2011 | Female/53 | Left | Left | TTF-1+; ER-; PR-; Mammaglobin- |
| Ko et al[15], 2012 | Female/47 | Right | Right | TTF-1+; ER-; PR-; Mammaglobin- |
| Beancic et al[16], 2012 | Female/55 | Left | Left | TTF-1+; CK7+; CK20- |
| Sato et al[17], 2012 | Female/57 | Right | Right | TTF-1+; SP-A+; MUC1+; ER-; PR-; CK7-; GCDFP15+; Mammaglobin+; ER-; PR-; CK5/6-; Calretinin +; CA125+; Thyroglobulin- |
| Ji et al[18], 2012 | Female/49 | Right | Left | TTF-1+; CK7+; CK20+; |
| Wang et al[19], 2009 | Female/51 | Left | Left | TTF-1+; CK7+; CEA+; GCDFP15-; Mammaglobin+; ER-; PR-; MUC2-; CK20-; SP-A-; GCDFP15-; MUC1+; ALK- |
| Maounis et al[20], 2010 | Female/73 | Left | Left | TTF-1+; SP-A+; MUC1+; ER-; PR-; CK5/6-; Calretinin +; CA125+; Thyroglobulin- |
| Huang et al[21], 2013 | Female/70 | Left | Left | TTF-1+; ER-; PR-; GCDFP15-; |
| Huang et al[22], 2013 | Female/48 | Right | Right | NA |
| Huang et al[23], 2013 | Female/43 | Right | Right | NA |
| Huang et al[24], 2013 | Female/54 | Left | Left | NA |
| Huang et al[25], 2013 | Female/52 | Left | Left | NA |
| Huang et al[26], 2013 | Female/43 | Left | Left | NA |
| Sanguinetti et al[27], 2013 | Female/43 | Left | Left | TTF-1+; SP-A+; MUC1+; ER-; PR-; CK5/6-; Calretinin +; CA125+; Thyroglobulin- |
| Liu et al[28], 2013 | Female/70 | Right | Right | TTF-1+; ER-; PR-; HER2- |
| Sousaris et al[29], 2013 | Female/55 | Left | Right | TTF-1+; Napsin A+; ER-; PR-; MUC2+; CK7-; GCDFP15+; Mammaglobin+; ER-; PR-; CK5/6-; Calretinin +; CA125+; Thyroglobulin- |
| Jeong et al[30], 2014 | Female/47 | Left | Left | TTF-1+; CK7+; Napsin A+; ER-; PR-; GCDFP15+; Mammaglobin+; ER-; PR-; CK5/6-; Calretinin +; CA125+; Thyroglobulin- |
| Mirrielle et al[31], 2014 | Female/58 | Left | Left | TTF-1+; ER+; PR+; HER2- |
| Hachisuka et al[32], 2014 | Female/60 | Right | Right | TTF-1+; Napsin A+; ER-; PR-; HER2-; SP-A+; GCDFP15+; Mammaglobin+; ER-; PR-; CK5/6-; Calretinin +; CA125+; Thyroglobulin- |
| Dansin et al[33], 2015 | Female/52 | Left | Left | TTF1+; ER+; PR+; HER2-; GATA3+; GCDFP15+; PAX8- |
| Venkatesulu et al[34], 2015 | Female/30 | Right | Right | TTF1+; ER+; PR+; HER2- |
| Authors          | Year | Gender | Age | Side | Histology                                                                 |
|------------------|------|--------|-----|------|---------------------------------------------------------------------------|
| Shen et al       | 2015 | Female | 52  | Right | TTF-1; CK7+; Napsin A+; ER-; PR-; GCDFP15-; Mammaglobin-                  |
| Gao et al        | 2016 | Female | 45  | Right | TTF-1; CK7+; Napsin A+; ROS1+; ER-; PR-; GCDFP15-; Mammaglobin-HER2; P63-|
| Bhanu et al      | 2016 | Female | 30  | Right | TTF-1; GCDFP15-; Mammaglobin-                                            |
| Erhamamci et al  | 2016 | Male   | 74  | Right | NA                                                                         |
| Ninan et al      | 2016 | Female | 67  | Right | CK7+; TTF-1; Napsin A+; GCDFP15-; GATA3-                                  |
| Ozturk et al     | 2017 | Male   | 63  | Left  | CK7+; TTF-1; Napsin A+; GCDFP15-; Mammaglobin-HER2; P63-                 |
| Cserni           | 2017 | Female | 45  | Left  | CK7+; TTF-1; Napsin A+; GCDFP15-; Mammaglobin-HER2; P63-                 |
| Al-Zawi et al    | 2017 | Female | 84  | Left  | CK7+; TTF-1; CK5-; P63-; ER-; GCDFP15-; HER2-; ALK-                      |
| Ali et al        | 2017 | Female | 64  | NA    | TTF-1; ER-; HER2-                                                         |
|                 |      | Female | 70  | NA    | TTF-1; Napsin A+; ER-; HER2-                                              |
|                 |      | Female | 59  | NA    | TTF-1; Napsin A+; ER-; HER2-                                              |
|                 |      | Female | 63  | NA    | TTF-1; Napsin A+; ER-; HER2-                                              |
|                 |      | Female | 45  | NA    | TTF-1; Napsin A+; ER-; HER2-                                              |
|                 |      | Female | 65  | NA    | TTF-1; Napsin A+; ER-; HER2-                                              |
|                 |      | Female | 69  | NA    | TTF-1; Napsin A+; ER-; HER2-                                              |
|                 |      | Female | 64  | NA    | TTF-1; Napsin A+; ER-; HER2-                                              |
| Ota et al        | 2018 | Female | 69  | Left  | CK7+; CK20- ; TTF-1; Napsin A+; ER-; PR-; GCDFP15-                        |
| Our case         |      | Female | 29  | Right | AE1AE3+; CK7+; TTF-1; Napsin A+; PR-; GCDFP15-15; MAMMAGLOBIN-HER2-      |

IHC: Immunohistochemistry; NA: Not available; ER: Estrogen receptor; PR: Progesterone receptor; HER2: Human epithelial growth factor receptor 2; TTF-1: Thyroid transcription factor 1; CK7: Cytokeratin 7; CK20: Cytokeratin 20; CK4: Cytokeratin 4; GCDFP15: Gross cystic disease fluid protein 15; SP-A: Surfactant A; CK5/6: Cytokeratin 5/6; MUC1: Mucin 1; MUC2: Mucin 2; ALK: Anaplastic lymphoma kinase; GATA3: GATA-binding protein 3; PAX8: Paired box gene 8; P63: Transformation-related protein 63.
Figure 4  Distribution of immunohistochemical markers on the breast biopsies in the reviewed cases (including ours). ER: Estrogen receptor; PR: Progesterone receptor; HER2: Human epithelial growth factor receptor 2; TTF-1: Thyroid transcription factor 1; CK7: Cytokeratin 7; CK20: Cytokeratin 20; GCDFP15: Gross cystic disease fluid protein 15; GATA3: GATA-binding protein 3.

REFERENCES

1 Lee AH. The histological diagnosis of metastases to the breast from extramammary malignancies. *J Clin Pathol* 2007; 60: 1333-1341 [PMID: 18042689 DOI: 10.1136/jcp.2006.046078]

2 Alva S, Shetty-Alva N. An update of tumor metastasis to the breast data. *Arch Surg* 1999; 134: 450 [PMID: 10199322 DOI: 10.1001/archsurg.134.4.450]

3 Lee SH, Park JM, Kook SH, Han BK, Moon WK. Metastatic tumors to the breast: mammographic and ultrasonographic findings. *J Ultrasound Med* 2000; 19: 257-262 [PMID: 10759349 DOI: 10.7863/jum.2000.19.4.257]

4 Masmoudi A, Mathieu MC, Soria JC. Breast metastasis from lung adenocarcinoma: a case report. *Anticancer Res* 2003; 23: 1825-1826 [PMID: 12820464]

5 Ramar K, Pervez H, Potti A, Mehdi S. Breast metastasis from non-small-cell lung carcinoma. *Med Oncol* 2003; 20: 181-184 [PMID: 12835222 DOI: 10.1385/MO:20:2:181]

6 Yeh CN, Lin CH, Chen MF. Clinical and ultrasonographic characteristics of breast metastases from extramammary malignancies. *Am Surg* 2004; 70: 287-290 [PMID: 15098776]

7 Komorowski AL, Wysocki WM, Mitus J. Metastasis to the breast--a clinical challenge in outpatient. *Acta Chir Belg* 2005; 105: 59-61 [PMID: 15790204]

8 Gómez-Caro A, Piñero A, Roca MJ, Torres J, Ferri B, Galindo PJ, Parrilla P. Surgical treatment of solitary metastasis in the male breast from non-small cell lung cancer. *Breast J* 2006; 12: 366-367 [PMID: 16848849 DOI: 10.1111/j.1075-122X.2006.00278.x]

9 Ucar N, Kurt OK, Alpar S, Orsel O, Demirag F, Kurt B. Breast metastasis in a male patient with nonsmall cell lung carcinoma. *South Med J* 2007; 100: 850-851 [PMID: 17715476 DOI: 10.1097/SMJ.0b013e3180f0265c]

10 Ho L, Henderson R, Seto J. Breast metastasis from poorly differentiated adenocarcinoma of the lung on PET-CT. *Clin Nucl Med* 2007; 32: 160-161 [PMID: 17242579 DOI: 10.1097/0.3.18063320.162574.4d]

11 Rimmer A, Rosenzweig KE. Palliative radiation for lung cancer metastases to the breast: two case reports. *J Thorac Oncol* 2007; 2: 1133-1135 [PMID: 18098558 DOI: 10.1097/JTO.0b013e318128a7ba]

12 Fulciniti F, Losito S, Botti G, Di Mattia D, La Mura A, Pisano C, Pignata S. Metastases to the breast: role of fine needle cytology samples. Our experience with nine cases in 2 years. *Ann Oncol* 2008; 19: 682-687 [PMID: 18048381 DOI: 10.1093/annonc/mdm546]

13 Klingens TA, Klaasen H, Aas H, Chen Y, Akslen LA. Secondary breast cancer: a 5-year population-based study with review of the literature. *APMIS* 2009; 117: 762-767 [PMID: 19775345 DOI: 10.1111/j.1600-0463.2009.02529.x]

14 Wang SC, Tseng JC, Yu CP, Cheng MF, Perng WC, Chen CW. Breast Metastasis from Lung Adenocarcinoma in a 26-year-old Woman: A Case Report. *Thorac Med* 2009; 24: 116-121 [DOI: 10.29806/TM.200904.0007]

15 Babu KS, Roberts F, Bryden F, McCafferty A, Downer P, Hansell DT, Jones R, Milroy R. Metastases to breast from primary lung cancer. *J Thorac Oncol* 2009; 4: 540-542 [PMID: 19333072 DOI: 10.1097/JTO.0b013e3181a58f6f]
M. Breast metastasis from EGFR-mutated lung adenocarcinoma: A case report and review of the literature.

Virchows Arch 2018; 472(a mimic of primary breast carcinoma-case series and literature review).

Ali RH, Taraboanta C, Mohammad T, Hayes MM, Ionescu DN. Metastatic non-small cell lung carcinoma with metastasis to the ipsilateral breast-a case report. J Thorac Sci 2011; 36: 37-40

Ko K, Ro JY, Hong EK, Lee S. Micropapillary lung cancer with breast metastasis simulating primary breast cancer due to architectural distortion on images. Korean J Radiol 2012; 13: 249-253 [PMID: 22438695 DOI: 10.3348/kjr.2012.13.2.249]

Branica BV, Meniga IN, Puljić I, Marusić A, Chalfe N, Ivcević A. Breast metastasis from lung adenocarcinoma diagnosed with fine needle aspiration cytology: a case report. Coll Antropol 2012; 36: 1461-1465 [PMID: 23390851]

Sato K, Takeyama Y, Yoshihara M, Kato T, Hashimoto H, Fukuy, Gonda H, Suzuki R. CBDA + Pemetrexed + Bevacizumab and Its Maintenance Chemotherapy in a Case of Solitary Breast Metastasis from a Lung Adenocarcinoma Resistant to Gefitinib. Case Rep Oncol 2012; 5: 546-553 [PMID: 23193670 DOI: 10.1159/000343678]

Jeong YJ, Gao P, Wang JG, Zhao J, Zhao P. Contralateral breast metastasis from pulmonary adenocarcinoma: two cases report and literature review. J Thorac Dis 2012; 4: 384-389 [PMID: 22931411 DOI: 10.3978/j.issn.2072-1439.2012.02.03]

Huang HC, Häng JF, Wuu MH, Chiu TY, Chiu CH. Lung adenocarcinoma with ipsilateral breast metastasis: a simple coincidence? J Thorac Oncol 2013; 8: 974-979 [PMID: 23774384 DOI: 10.1097/JTO.0b013e31828b6873]

Sanguinetti A, Puma F, Lucchini R, Santoprete S, Cirocchi R, Corsi A, Triola R, Avena N. Breast metastasis from a pulmonary adenocarcinoma: Case report and review of the literature. Oncol Lett 2013; 5: 328-332 [PMID: 23525943 DOI: 10.3892/ol.2012.997]

Liam CK, Pang YK, Poh ME, Kow KS, Wong CK, Varughese R. Advanced right lung adenocarcinoma with ipsilateral breast metastasis. Respiril Case Rep 2013; 1: 20-22 [PMID: 25475351 DOI: 10.1016/j.rec.2014.01.014]

Souardis N, Mendelson G, Barr RG. Lung cancer metastatic to breast: case report and review of the literature. Ultrasound Q 2013; 29: 205-209 [PMID: 23975047 DOI: 10.1097/RUQ.0b013e3182a0d6c]
Enrico D et al. Breast metastasis from primary lung adenocarcinoma in a young woman

Clin Case Rep 2018; 6: 1510-1516 [PMID: 30147894 DOI: 10.1002/ccr3.1636]

45 Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, Hizawa N. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol 2015; 3: 217-221 [PMID: 25869298 DOI: 10.3892/mco.2014.410]

46 Williams SA, Ehlers RA 2nd, Hunt KK, Yi M, Kuerer HM, Singleterry SE, Ross MI, Feig BW, Symmans WF, Meric-Bernstam F. Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival. Cancer 2007; 110: 731-737 [PMID: 17582626 DOI: 10.1002/cncr.22835]

47 Lee SK, Kim WS, Kim EH, Hur SM, Kim SY, Cho EY, Han SY, Hahn BK, Choe JH, Kim JH, Kim JS, Lee JH, Nam SJ, Yang JH. Characteristics of metastasis in the breast from extramammary malignancies. J Surg Oncol 2010; 101: 137-140 [PMID: 20082359 DOI: 10.1002/jso.21453]

48 Gomez-Fernandez C, Mejias A, Walker G, Nadji M. Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung: the antibody factor. Appl Immunohistochem Mol Morphol 2010; 18: 137-141 [PMID: 19875957 DOI: 10.1097/PAI.0b013e3181bec23b]

49 Provenzano E, Byrne DJ, Russell PA, Wright GM, Generali D, Fox SB. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours. Histopathology 2016; 68: 367-377 [PMID: 26118394 DOI: 10.1111/his.12765]

50 Turner BM, Cagle PT, Sainz JM, Fukuoka J, Shen SS, Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med 2012; 136: 163-171 [PMID: 22288963 DOI: 10.5858/arpa.2011-0320-OA]

51 Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, Langfort R, Waloszczyk P, Biernat W, Lasota J, Wang Z. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol 2014; 38: 13-22 [PMID: 24145643 DOI: 10.1097/PAS.0b013e3182a02181]

52 Barber TW, Hofman MS, Hicks RJ. Breast lymphatic drainage via the pulmonary lymphatic system. Eur J Nucl Med Mol Imaging 2010; 37: 2203 [PMID: 20821209 DOI: 10.1007/s00259-010-1595-z]
